Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Article Abstract:
An oral prodrug of LY404039 (LY2140023) is evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study in order to test if metabotropic glutamate 2/3 (mGlu2/3) receptor agonists work by a distinct mechanism different from that of olanzapine. The results have shown that mGlu2/3 receptor agonists have antipsychotic properties and might provide a new alternative for the treatment of schizophrenia.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Schizophrenia drug says goodbye to dopamine
Article Abstract:
A novel class of drugs that activate group II metabotropic glutamate receptors (mGluR2 and mGluR3), which bind glutamate and signal through G proteins and cyclic mononucleotides, is designed and tested. This drug has offered promise for a new class of anti-psychotic therapeutics and has represented a potential sea change in the pharmacological approach to schizophrenia.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Dopamine covalently modifies and functionally inactivates parkin
Article Abstract:
A report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function is presented. In the brains of individuals with sporadic Parkinson disease, the results reveal decreases in parkin solubility consistent with its functional inactivation.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial
- Abstracts: Predictors of antiretroviral treatment failure in an Urban HIV clinic. In vitro and in vivo: The story of nonoxynol 9
- Abstracts: Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Targeted cancer therapeutics: The heartbreak of success
- Abstracts: The changing approach to the treatment of early breast cancer. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors
- Abstracts: Growth hormone therapy in critically ill patients. Increased mortality associated with growth hormone treatment in critically ill adults